Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (ChiCTR2600132739) titled 'A Single-Center, Open-Label, Dose-Escalation Phase Ib Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of the PD-L1/4-1BB Bispecific Antibody ATG-101 in Patients with Second-Line and Beyond Extrapulmonary Neuroendocrine Neoplasms' on Sept. 17.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Beijing GoBroad Hospital
Condition:
NEC/NET G3
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-09-21
Target Sample Size: Test group:30;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?...